AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

At the Goldman Sachs Healthcare Conference, AbbVie's management, led by CEO Robert Michael, highlighted the company's strong performance and future growth prospects, exceeding peak revenue just two years post-HUMIRA U.S. LOE. Executives addressed concerns about drug pricing pressures, emphasizing productive dialogue with the administration and advocating for PBM reform and fair international trade practices. AbbVie raised its 2025 guidance, driven by robust growth in immunology (SKYRIZI and RINVOQ), neuroscience, and oncology, while adjusting aesthetics expectations downward due to economic headwinds; the company is focused on early-stage business development deals to drive growth beyond the next eight years, including a focus on obesity with the Gubra asset.

Analysis

AbbVie (ABBV) management presented a highly confident outlook at the Goldman Sachs Healthcare Conference dated June 10, 2025, detailing significant financial outperformance and strategic initiatives positioning the company for sustained growth. AbbVie has surpassed its pre-HUMIRA U.S. Loss of Exclusivity (LOE) peak revenue within two years, an achievement CEO Robert Michael termed unprecedented, and projects a clear growth runway for at least the next eight years, with neuroscience anticipated to become the industry's leading business by revenue in 2026, surpassing Roche. This optimism is reflected in raised 2025 full-year guidance, with anticipated total sales of $59.7 billion, propelled by robust Q1 2025 results where the ex-HUMIRA business grew approximately 23% operationally year-over-year and is guided for 15% full-year growth, now representing 90% of total revenue. Key immunology products SKYRIZI and RINVOQ saw their combined 2025 guidance increased by $900 million, driven by strong uptake including capturing one in two new/switching Crohn's patients and one in three in ulcerative colitis; neuroscience guidance was increased by $200 million — led by BOTOX Therapeutics, the oral CGRP franchise, and strong international uptake of VYALEV (with U.S. Medicare reimbursement expected in late 2025 and current year sales guided at $300 million) — and oncology by $200 million. In contrast, aesthetics guidance was lowered by $200 million due to macroeconomic pressures, though market stabilization and the upcoming TrenibotE toxin approval in early 2026 offer potential upside. Management addressed drug pricing concerns, noting productive engagement with the administration on policies like the Most Favored Nation (MFN) executive order and Pharmacy Benefit Manager (PBM) reform, asserting AbbVie's ability to compete effectively based on product differentiation. The company's business development strategy is heavily focused on early-stage assets, with over 25 deals executed since the beginning of 2024 to secure future growth, including a strategic entry into the obesity market with the Gubra (amylin-based) asset and continued investment in its rapidly expanding neuroscience portfolio, which includes the Parkinson's drug Tavapadon (filing expected late 2025, launch in 2026). Pipeline advancements are critical, with upcoming Phase III data for RINVOQ in hidradenitis suppurativa (HS) in 2026, and the development of Lutikizumab for HS. In oncology, AbbVie is advancing its BCMA bispecific, 383 (Etentamig), to Phase III for multiple myeloma, emphasizing its potential for a more favorable outpatient administration profile. AbbVie's operational efficiency, with a guided 46.5% operating margin for 2025, has allowed continued R&D investment without major cost reductions.

Key Decisions for Investors

• Investors should recognize AbbVie's demonstrated ability to grow robustly post-HUMIRA LOE, driven by its diversified ex-HUMIRA platform, which supports the company's positive multi-year outlook and recently increased 2025 financial guidance.
• While management expresses confidence in navigating the evolving U.S. drug pricing landscape through dialogue and product innovation, ongoing monitoring of regulatory developments, including PBM reform and international pricing pressures, remains crucial.
• The strategic focus on early-stage business development, particularly the entry into the large obesity market with the Gubra asset and the strengthening of the neuroscience franchise with products like VYALEV and the pipeline candidate Tavapadon (launching 2026), presents significant long-term value creation opportunities.
• Despite near-term softness in the aesthetics market, the potential for stabilization and the introduction of innovative products such as TrenibotE in early 2026 could provide a catalyst for this segment's recovery and future contribution.